The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model

被引:86
作者
Schmitz, N
Kurrer, M
Kopf, M
机构
[1] Univ Hosp, Dept Pathol, Zurich, Switzerland
[2] Swiss Fed Inst Technol, Zurich, Switzerland
关键词
IL-1; asthma; airway inflammation; eosinophilia; Th2; response;
D O I
10.1002/eji.200323801
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IL-1alpha and IL-1beta are potent pro-inflammatory cytokines that regulate many physiological systems by binding and signaling to the same receptor termed IL-1 receptor type 1 (IL-1R1). We have investigated the role of IL-1 for pulmonary immune responses in models of allergic asthma using IL-1R1-deficient (IL-1R1(-/-)) mice. In a model of mild asthma, based on repeated sensitization of mice with low doses of ovalbumin in the absence of any adjuvant and multiple intranasal challenges, the pulmonary eosinophilic inflammation and goblet cell hyperplasia were strongly reduced in IL-1R1(-/-) as compared to control BALB/c mice. Moreover, priming of CD4(+) T cells in bronchial lymph nodes and their recruitment to the lung was affected in IL-1R1(-/-) mice associated with impaired antibody responses including IgG, IgE, and IgA. In contrast, sensitization of mice in the presence of alum adjuvant, a more severe asthma model, rendered the IL-1 pathway dispensable for the development of pulmonary allergic Th2 responses, as eosinophilic inflammation, antibody responses, and CD4(+) T cell priming in lymph nodes were comparable between IL-1R1(-/-) and wild-type mice. These results suggest a critical role of IL-1 /IL-1R1 for development of allergic Th2 responses, but its requirement can be overcome by using alum as adjuvant for sensitization.
引用
收藏
页码:991 / 1000
页数:10
相关论文
共 31 条
  • [1] Interleukin-1 receptor antagonist: Role in biology
    Arend, WP
    Malyak, M
    Guthridge, CJ
    Gabay, C
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 : 27 - 55
  • [2] BORISH L, 1992, J IMMUNOL, V149, P3078
  • [3] EOSINOPHILIC INFLAMMATION IN ASTHMA
    BOUSQUET, J
    CHANEZ, P
    LACOSTE, JY
    BARNEON, G
    GHAVANIAN, N
    ENANDER, I
    VENGE, P
    AHLSTEDT, S
    SIMONYLAFONTAINE, J
    GODARD, P
    MICHEL, FB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) : 1033 - 1039
  • [4] Broide DH, 2000, BLOOD, V95, P263
  • [5] Cytokines in asthma
    Chung, KF
    Barnes, PJ
    [J]. THORAX, 1999, 54 (09) : 825 - 857
  • [6] THE TYPE-II DECOY RECEPTOR - A NOVEL REGULATORY PATHWAY FOR INTERLEUKIN-1
    COLOTTA, F
    DOWER, SK
    SIMS, JE
    MANTOVANI, A
    [J]. IMMUNOLOGY TODAY, 1994, 15 (12): : 562 - 566
  • [7] CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model
    Deurloo, DT
    van Esch, BCAM
    Hofstra, CL
    Nijkamp, FP
    van Oosterhout, AJM
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2001, 25 (06) : 751 - 760
  • [8] Biologic basis for interleukin-1 in disease
    Dinarello, CA
    [J]. BLOOD, 1996, 87 (06) : 2095 - 2147
  • [9] INTERLEUKIN-1
    DINARELLO, CA
    [J]. REVIEWS OF INFECTIOUS DISEASES, 1984, 6 (01): : 51 - 95
  • [10] Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen
    Eisenbarth, SC
    Piggott, DA
    Huleatt, JW
    Visintin, I
    Herrick, CA
    Bottomly, K
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (12) : 1645 - 1651